British Bio-technology Group plc announced that its scientistshave discovered three new potential drug leads, and theOxford, England, company (NASDAQ:BBIOY) has filed patentapplications on each.

Two of these are chemical entities: BB-2275, an inhibitor oftumor necrosis factor, will be developed as a treatment forcachexia, and BB-2113, a platelet activating factor antagonist,will be developed for treating acute cardiovascular diseases.British Bio-tech's third new compound, stem cell protector, is agenetically engineered protein that could be used to reduce thebone marrow toxicity of existing anti-cancer therapies.

(c) 1997 American Health Consultants. All rights reserved.